Showing 1721-1730 of 5643 results for "".
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- Eyevance’s Natacyn Now Available for Next-Day Deliveryhttps://modernod.com/news/eyevances-natacyn-now-available-next-day/2478883/Eyevance Pharmaceuticals announced that its anti-fungal ophthalmic medication, Natacyn (natamycin ophthalmic suspension 5%), is now available for next-day delivery. Natacyn, which Eyevance acquired from Novartis in 2019, is indicated for the treatment of fungal blepharitis, conjunctivitis,
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- Nova Eye Medical Acquires Molteno3 Glaucoma Drainage Device Portfoliohttps://modernod.com/news/nova-eye-medical-acquires-molteno3-glaucoma-drainage-device-portfolio/2477974/Nova Eye Medical has completed the acquisition of ophthalmic assets from Molteno Ophthalmic Limited, including the proprietary Molteno3 glaucoma drainage device (GDD) platform. Terms of th
- Dyno Therapeutics Collaborates With Novartis to Develop Improved Gene Therapies With AAV Vectors Based on AI Technologyhttps://modernod.com/news/dyno-therapeutics-collaborates-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/2477740/Dyno Therapeutics announced a collaboration with Novartis to develop improved adeno-associated virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. Financial terms of the deal were not disclosed. The partnership will allow the p
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro
- Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minuteshttps://modernod.com/news/abbott-launches-molecular-point-of-care-test-to-detect-novel-coronavirus-in-as-little-as-five-minutes/2477479/Abbott announced that the FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as 5 minutes and negative results in 13 minutes, according to a company new